295 related articles for article (PubMed ID: 29897562)
1. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
2. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Ellingson BM; Abrey LE; Nelson SJ; Kaufmann TJ; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Butowski N; Ligon KL; Gerstner ER; Colman H; de Groot J; Chang S; Mellinghoff I; Young RJ; Alexander BM; Colen R; Taylor JW; Arrillaga-Romany I; Mehta A; Huang RY; Pope WB; Reardon D; Batchelor T; Prados M; Galanis E; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Aug; 20(9):1240-1250. PubMed ID: 29660006
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Boxerman JL; Zhang Z; Safriel Y; Rogg JM; Wolf RL; Mohan S; Marques H; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2018 Sep; 20(10):1400-1410. PubMed ID: 29590461
[TBL] [Abstract][Full Text] [Related]
4. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
[TBL] [Abstract][Full Text] [Related]
5. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
7. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
9. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S; Schaub C; Junold N; Hattingen E; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Galldiks N; Weller J; Mack F; Tzaridis T; Bähr O; Seidel C; Schlegel U; Schmidt-Graf F; Rohde V; Borchers C; Tabatabai G; Hänel M; Sabel M; Gerlach R; Krex D; Belka C; Vatter H; Proescholdt M; Glas M; Herrlinger U
J Neurooncol; 2019 Sep; 144(3):501-509. PubMed ID: 31325144
[TBL] [Abstract][Full Text] [Related]
10. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
11. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
12. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Lupo JM; Essock-Burns E; Molinaro AM; Cha S; Chang SM; Butowski N; Nelson SJ
Neuro Oncol; 2013 Apr; 15(4):480-9. PubMed ID: 23393208
[TBL] [Abstract][Full Text] [Related]
13. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Galanis E; Anderson SK; Miller CR; Sarkaria JN; Jaeckle K; Buckner JC; Ligon KL; Ballman KV; Moore DF; Nebozhyn M; Loboda A; Schiff D; Ahluwalia MS; Lee EQ; Gerstner ER; Lesser GJ; Prados M; Grossman SA; Cerhan J; Giannini C; Wen PY;
Neuro Oncol; 2018 Mar; 20(4):546-556. PubMed ID: 29016887
[TBL] [Abstract][Full Text] [Related]
15. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
[TBL] [Abstract][Full Text] [Related]
16. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Werner-Wasik M; Shih HA; Ashby LS; Michael Yu HH; Stieber VW; Malone SC; Fiveash JB; Mohile NA; Ahluwalia MS; Wendland MM; Stella PJ; Kee AY; Mehta MP
Neuro Oncol; 2018 Apr; 20(5):666-673. PubMed ID: 29126203
[TBL] [Abstract][Full Text] [Related]
19. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
